Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib and Ropeginterferon in Newly Diagnosed CML
NCT03831776Phase 2Completed
- Sponsor
- St. Olavs University Hospital
- Start
- Mar 2019
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of ropeginterferon alfa-2b in chronic myeloid leukemia (CML) (2 arms), sponsored by St. Olavs University Hospital. Primary endpoint: Molecular Response 4 at 12 months. Started Mar 2019; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03831776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831776.